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Type 2 diabetes mellitus (T2DM) is the most common human endocrine disease and is characterized by peripheral insulin
resistance and pancreatic islet β-cell failure. Accumulating evidence indicates that mitochondrial dysfunction is a central
contributor to β-cell failure in the evolution of T2DM. As reviewed elsewhere, reactive oxygen species (ROS) produced by β-cell
mitochondria as a result of metabolic stress activate several stress-response pathways. This paper focuses on mechanisms whereby
ROS aﬀect mitochondrial structure and function and lead to β-cell failure. ROS activate UCP2, which results in proton leak across
the mitochondrial inner membrane, and this leads to reduced β-cell ATP synthesis and content, which is a critical parameter in
regulating glucose-stimulated insulin secretion. In addition, ROS oxidize polyunsaturated fatty acids in mitochondrial cardiolipin
and other phospholipids, and this impairs membrane integrity and leads to cytochrome c release into cytosol and apoptosis. Group
VIA phospholipase A2 (iPLA2β) appears to be a component of a mechanism for repairing mitochondrial phospholipids that
contain oxidized fatty acid substituents, and genetic or acquired iPLA2β-deficiency increases β-cell mitochondrial susceptibility
to injury from ROS and predisposes to developing T2DM. Interventions that attenuate ROS eﬀects on β-cell mitochondrial
phospholipids might prevent or retard development of T2DM.
1. Introduction
Type 2 diabetes mellitus (T2DM) is the most common
human endocrine disease and is reaching pandemic propor-
tions [1]. Predisposition to T2DM is aﬀected both by genetic
and acquired factors, and there are contributions from many
genes and environmental influences that are incompletely
understood [1, 2]. It is becoming clear that the progressive
failure of pancreatic islet β-cells is a central component of the
development and progression of T2DM [3]. Normally, pan-
creatic islet β-cells respond to increased metabolic demands
by increasing their mass and insulin synthetic and secretory
activity, as demonstrated both in rodent models of obesity
without diabetes and in nondiabetic obese humans.
Most humans who are obese do not develop diabetes,
and T2DM develops only in those who are unable to sustain
compensatory β-cell responses to increasing metabolic
stress [4]. The United Kingdom Prospective Diabetes Study
(UKPDS) has clearly demonstrated that the progressive
nature of T2DM reflects an ongoing decline in β-cell func-
tion without a change in insulin sensitivity [5]. Longitudinal
studies of subjects who eventually develop T2DM reveal a
progressive rise in serum insulin levels in the prediabetic
phase that is followed by a decline in serum insulin levels
upon development of fasting hyperglycemia [1]. Many
T2DM patients ultimately require therapy with exogenous
insulin in the later stages of the disease because endogenous
insulin production becomes insuﬃcient to maintain accept-
able levels of glycemia despite ongoing therapy with other
antidiabetic agents, including sulfonylureas and metformin,
inter alia [3].
Reductions in both β-cell mass and function contribute
to the pathogenesis of β-cell failure in human T2DM [6, 7].
Several studies have demonstrated that glucose-stimulated
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insulin secretion is lower in islets from T2DM patients com-
pared to control islets [8, 9]. In addition, islets from T2DM
subjects exhibit both structural and functional abnormalities
and fail to reverse hyperglycemia when transplanted into
diabetic mice under conditions in which equivalent numbers
of control human islets do so [9]. Interestingly, T2DM
human islets secrete significantly higher amounts of insulin
in response to arginine and glibenclamide than in response
to D-glucose, suggesting that T2DM β-cell insulin secretory
defects reflect a relatively selective loss of responsivity to
glucose compared to other insulin secretagogues [10].
Moreover, it has been demonstrated that the ATP content
of islets from T2DM subjects fails to increase normally upon
acute stimulation with glucose. Consequently, their ATP/
ADP ratio rises to values only about 60% of that in control
islets, and this is likely to account for or contribute to
the blunted or absent glucose-stimulated insulin secretory
responses of T2DM islets [11]. Mitochondria in T2DM β-
cells exhibit both morphologic and functional abnormalities
that are not observed in control β-cells [11]. Together,
these findings indicate that human T2DM β-cells exhibit
abnormalities in glucose metabolism and in mitochondrial
structure and function that result in impaired ATP produc-
tion and glucose-stimulated insulin secretion [7].
Accumulating evidence indicates that progressive reduc-
tion in β-cell mass also contributes to the overall decline in
β-cell functional capacity in the pathogenesis of T2DM. Early
observations indicated that β-cell volume is significantly
reduced in T2DM islets [12–14]. More recent studies with
postmortem and surgical specimens of human pancreata
have characterized changes in β-cell mass that occur during
the evolution of T2DM [6, 15]. One such study based on
specimens from 124 autopsies revealed a 63% lower β-cell
volume in obese T2DM subjects compared to nondiabetic,
weight-matched control subjects and a 41% lower β-cell
volume in lean T2DM subjects compared to nondiabetic
lean control subjects. Another study revealed a 40% lower
β-cell mass in subjects with elevated fasting blood glucose
levels compared to weight-matched control subjects with
fasting euglycemia, which suggests that reductions in β-cell
mass may not be confined to late-stage T2DM but may
rather occur progressively throughout the prediabetic phase
and continue after the onset of impaired glucose tolerance
and then hyperglycemia [6]. Moreover, the decreased β-
cell volume observed in subjects with fasting hyperglycemia
is associated with increased β-cell death by apoptosis [6].
Evidence also indicates that the loss of β-cells is selective
among islet cell types in the evolution of T2DM and that
comparable losses of islet α-cells do not occur [15]. Together,
these findings demonstrate that progressive structural and
functional abnormalities occur in islets during the develop-
ment of T2DM.
The mechanisms that underlie the progressive devel-
opment of β-cell failure during the evolution of T2DM
are not fully understood at present [3]. Identifying the
factors involved and characterizing the mechanisms by
which they lead to β-cell failure would be important steps
in elucidating the pathogenesis of T2DM and identifying
potential targets for therapeutic interventions designed to
retard or prevent these processes. Both genetic and acquired
factors contribute to β-cell failure in T2DM [16], and, among
the acquired factors, glucotoxicity, lipotoxicity, altered islet
amyloid polypeptide (IAPP) processing, advanced glycation
end-products (AGEs), and increased inflammatory cytokines
have been suggested to contribute to β-cell injury [1, 7, 17–
20].
Although many mechanisms are proposed to underlie
eﬀects of these factors, a unifying theme is that production
of reactive oxygen species (ROS) induced by metabolic stress
represents a common pathway of injury in the cascade of
events that ultimately results in β-cell failure [3, 21–27].
Activation of a series of stress-response pathways by ROS has
been reviewed elsewhere [28–30]. The purpose of our paper
is to provide a brief overview of how mitochondrial ROS
aﬀect mitochondrial membrane phospholipids, including
cardiolipin, and how this might lead to β-cell mitochondrial
failure and ultimately result in T2DM. Recent advances in
complex lipid analyses by mass spectrometry permit detailed
molecular characterization of the eﬀects of pathophysiologic
states on mitochondrial cardiolipin species [31–34], and
this provides a powerful tool with which to increase our
understanding of these processes and to identify potential
targets for therapeutic intervention.
2. Mitochondria Are the Most Important
Cellular Source of ROS in β-Cells
Oxidative stress can arise from various sources [35], and
ROS appear to be produced in larger amounts by islets from
T2DM patients than by those from nondiabetic subjects [23,
36–38]. Accumulating evidence indicates that obesity and
hyperglycemia are associated with increased ROS production
[22, 39]. Although ROS are generated in peroxisomes,
for example, by cytochrome P450- and NADPH oxidase-
catalyzed reactions, and in other nonmitochondrial loci, the
major source of ROS production in cells is the mitochon-
drion [40].
Electron flow through the mitochondrial electron-
transport chain is carried out by four inner membrane-
associated enzyme complexes (I–IV), cytochrome c, and
the mobile carrier coenzyme Q. Molecular species of ROS
include superoxide anion (O•−2 ), hydrogen peroxide (H2O2),
and the hydroxyl radical (•HO), inter alia. The electron-
transport chain continually generates small amounts of
superoxide anion radicals, principally through complexes I
and III [41]. Superoxide production increases substantially
in the settings of obesity and hyperglycemia [22, 39]. Super-
oxide radicals are normally removed by Mn2+-superoxide
dismutase (MnSOD), which dismutates O•−2 to produce
H2O2 that is then reduced to water by catalase or glutathione
peroxidase (GPx) at the expense of glutathione. When rates
of H2O2 generation exceed those of its removal, H2O2
accumulation can result in production of the highly reactive
hydroxyl radical in the presence of Fe2+ via the Fenton
reaction and via the Haber-Weiss reaction of O•−2 and •HO
(Figure 1).
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Figure 1: Mitochondrial ROS production and defense. The electron transport chain consists of four protein complexes (I–IV) and the ATP
synthase located in the inner mitochondrial membrane (IMM). The activity of complex I converts NADH to NAD+, and the activity of
complex II converts succinate to fumarate. Complexes I, III, and IV transport protons (H+) across the membrane, and complexes I and III
generate superoxide anion radical ( O•−2 ) during the electron transfer process. O
•−
2 can naturally dismutate to hydrogen peroxide (H2O2) or
is enzymatically dismutated by matrix manganese superoxide dismutase (MnSOD). O•−2 is not membrane permeable but can pass through
inner membrane ion channel (IMAC) and is dismutated to H2O2 by Cu/ZnSOD in the intermembrane space (IMS)/cytoplasm. H2O2 is
detoxified in the matrix by catalase and the glutathione peroxidase (GPx). Alternately, H2O2 can react with metal ions to generate via Fenton
chemistry (dash line) the highly reactive hydroxyl radical (•OH) that can initiate the peroxidation of the inner mitochondrial membrane
phospholipids, such as cardiolipin. Cyt. c: cytochrome c; IMS: intermembrane space; GSH: glutathione; GSSG: glutathione disulfide; ΔΨm:
membrane potential.
If they are not rapidly eliminated, ROS can injure
mitochondria by promoting DNA fragmentation, protein
crosslinking, and peroxidation of membrane phospholipids
and by activating a series of stress pathways [29]. Indeed, β-
cell mitochondria in islets from T2DM subjects have been
found to exhibit morphologic abnormalities that include
hypertrophy, a rounded rather than elliptical shape, and
higher density compared to β-cell mitochondria in islets
from control subjects [11, 42]
3. ROS Trigger Apoptosis via
Oxidation of Mitochondrial Inner Membrane
Phospholipids in β-Cells
The onset of T2DM is accompanied by a progressive decrease
in β-cell mass that results from a marked increase in β-
cell apoptosis [6, 7, 43], and mitochondria are known
to play a pivotal role in regulating apoptotic cell death
[44]. Proapoptotic stimuli induce release of cytochrome c
from mitochondria into the cytoplasm, where cytochrome c
participates in apoptosome formation that results in caspase-
9 activation and subsequent activation of the executioner
caspases 3, 6, and 7 that dismantle the cell during apoptosis
[44].
Cytochrome c release from mitochondria is a key step
in the initiation of apoptosis [45] and appears to result
from direct action of ROS on the mitochondrial phos-
pholipid cardiolipin [46, 47]. Cardiolipin is a structurally
unique dimeric phospholipid exclusively localized in the
inner mitochondrial membrane (IMM) in mammalian cells
and is essential for maintaining mitochondrial architecture
and membrane potential and for providing support to
proteins involved in mitochondrial bioenergetics [48, 49].
Cytochrome c is anchored to the outer surface of the inner
mitochondrial membrane by electrostatic and hydrophobic
interactions with cardiolipin [50]. During the early phase
of apoptosis, mitochondrial ROS production is stimulated,
and cardiolipin is oxidized. This destabilizes the interaction
with cytochrome c, which then detaches from the membrane
and is released into the cytoplasm through pores in the outer
membrane [46, 50].
Cardiolipin is particularly susceptible to oxidation
because it is enriched in polyunsaturated fatty acid (PUFA)
residues, especially linoleate (C18:2), which contain a
bisallylic methylene group from which hydrogen is easily
abstracted to provide a center for formation of a hydroperoxy
radical via interaction with molecular oxygen. Linoleic
acid (C18:2) is the most abundant fatty acid substituent
of cardiolipin in most mammalian tissues [51], and rat
pancreatic islet cardiolipin, for example, contains 89.5%
PUFA and 71% linoleate [52]. Mitochondrial cardiolipin
is also a target of the proapoptotic protein tBid, which
is a Bcl-2-family member produced from Bid by the
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activation of caspase-8. This results in activation of the
mitochondrial death pathway upon induction of apoptosis
via engagement of death receptors [53]. Cardiolipin serves
as a mitochondrial target of tBid, which promotes pore
formation in the outer mitochondrial membrane by Bax
or Bak in a process that is inhibited by Bcl-2 or Bcl-XL
[54].
The mitochondrial phospholipid cardiolipin is thus a
central participant in regulating apoptosis triggered by both
the mitochondrial- and death receptor-mediated pathways,
and alterations of mitochondrial cardiolipin are now rec-
ognized to be involved in the development of diabetes
and several other pathologic conditions [29, 33, 34, 48,
49, 55–61]. We have observed that generation of ROS by
mitochondria triggers apoptosis in INS-1 insulinoma cells
and inmouse pancreatic islet β-cells in a process that involves
mitochondrial phospholipid oxidation and cytochrome c
release [57, 62].
4. ROS Activate Uncoupling
Protein 2 (UCP2) through Initiation of
Phospholipid Peroxidation in β-Cells
Glucose-stimulated insulin secretion by residual β-cells is
impaired in subjects with T2DM [7]. Glucose sensing
in β-cells requires the coupling of glycolysis to oxidative
phosphorylation in mitochondria to produce ATP [28].
The respiratory chain complexes pump protons out of the
mitochondrial matrix to generate an electrochemical proton
gradient that provides the energy required by ATP synthase
to produce ATP from ADP. This glucose-stimulated ATP
production at the expense of ADP causes the cytoplasmic
ATP/ADP ratio to rise, which induces closure of ATP-
sensitive potassium channels (KATP), depolarization of the
plasma membrane, opening of voltage-gated calcium chan-
nels, influx of Ca2+, a rise in [Ca2+] in cytosol and other
cellular compartments, activation of Ca2+-sensitive eﬀector
elements including the Ca2+/calmodulin-dependent protein
kinase IIβ and others, and triggering of insulin exocytosis
[63]. That oxidative phosphorylation is essential to glucose-
stimulated insulin secretion is reflected by the observations,
inter alia, that specific inhibition of mitochondrial respira-
tory chain complexes by various means invariably results in
blockade of insulin secretion [64]. Moreover, mitochondrial
mutations that cause defects in insulin secretion underlie
maternally inherited T2DM [65–67].
It appears that pancreatic islet β-cell mitochondrial
membrane potential can be regulated by uncoupling protein-
2 (UCP2), which is a member of the mitochondrial anion
carrier protein (MACP) family. UCP2 facilitates proton leak
to reduce the mitochondrial membrane potential and thus
attenuates ATP synthesis. It has been reported that UCP2
negatively regulates insulin secretion and is a major link
between obesity, β-cell dysfunction, and T2DM [21, 68].
Obesity and chronic hyperglycemia increase mitochondrial
superoxide (O•−2 ) production [69], and this causes activation
of UCP2 and results in pancreatic islet β-cell dysfunction
[70–73]. Inhibition of UCP2-mediated proton leak by
Genipin has been found acutely to reverse obesity- and high-
glucose-induced β-cell dysfunction in isolated pancreatic
islets in vitro and in animals with diet-induced T2DM in vivo
[74, 75]. Together, these observations suggest that activation
of UCP2 by superoxide produced by mitochondria could
contribute to the development of β-cell dysfunction during
the evolution of T2DM.
The mechanism by which superoxide activates UCP2
is nonetheless not well understood at present, although
studies with probes targeted to subcellular compartments
have provided an outline of some possibly contributory
processes. Experiments with targeted antioxidants suggest
that superoxide or its products activate UCPs on the matrix
side of the mitochondrial inner membrane [71]. A study
with a mitochondrion-targeted spin trap derived from α-
phenyl-N-tert-butylnitrone indicated that superoxide acti-
vates UCPs via oxidation of unsaturated side chains of
fatty acid substituents in mitochondrial phospholipids, for
example, cardiolipin, associated with UCPs [76]. In this
model, superoxide generated by mitochondria is dismutated
by matrix Mn-SOD to hydrogen peroxide (H2O2), which
reacts with Fe2+ by the Fenton reaction to generate hydroxyl
radical (•OH). The hydroxyl radical extracts a hydrogen
atom (H•) from a bis-allylic methylene moiety of PUFA
substituent of a phospholipid, for example, cardiolipin.
The resultant carbon-centered radical reacts with molecular
oxygen (O2) to form a peroxy radical (HC-O-O•), which
then initiates a chain reaction of lipid peroxidation that
results in generation of a complex mixture of products,
including 4-hydroxynonenal (HNE) and 4-hydroxyhexenal,
which activate UCPs [76, 77].
Cardiolipin is a major phospholipid constituent of the
mitochondrial inner membrane, and the PUFA linoleate
is the major fatty acid substituent of β-cell cardiolipin
[52]. The electron transport chain complexes that generate
superoxide reside in the inner mitochondrial membrane, and
superoxide production is rate limiting for generating all ROS.
Cardiolipin PUFA substituents are especially susceptible to
reaction with ROS because of their bisallylic methylene
moieties. Like cardiolipin and the electron transport chain
complexes, UCP2 also resides in the inner mitochondrial
membrane. Together, these observations suggest a sequence
in which high rates of mitochondrial superoxide production
are associated with correspondingly high rates of cardiolipin
oxidation and that this contributes to superoxide-mediated
activation of UCPs, perhaps via the generation of HNE
and other lipid peroxidation breakdown products. Thus,
we propose that cardiolipin oxidation may directly link
ROS generation to UCP2 activation and thereby contribute
to acceleration of the proton leak that ultimately results
in β-cell dysfunction. Indeed, it was recently reported
that oxidation of a mitochondria-specific phospholipid
tetralinoleoyl cardiolipin (L4CL) leads to the formation
of 4-HNE via a novel chemical mechanism that involves
cross-chain peroxyl radical addition and decomposition
[78]. This proposal points to potentially important target
processes for the design of interventions to prevent or
retard the development of T2DM and perhaps obesity
[77].
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5. The Role of Group
VIA PLA2 (iPLA2β) in Remodeling and
Repairing Mitochondrial Membranes
Pancreatic islet cardiolipin is enriched in PUFA (89.5%)
substituents, including linoleate (71%) [52], and PUFA side
chains are especially vulnerable to oxidation because of their
bisallylic methylene moieties. Cardiolipin resides in the inner
mitochondrial membrane, which is the locus of ROS gener-
ation, and this spatial proximity would also favor cardiolipin
oxidation under conditions of accelerated ROS production.
This susceptibility would be expected to be enhanced in
islets, which express low levels of antioxidant enzymes
including superoxide dismutase (SOD), catalase, and glu-
tathione peroxidase (Gpx) compared to other tissues, such
as liver, kidney, brain, lung, muscles, pituitary gland, and
adrenal gland [36, 79–82]. To counteract the continual oxi-
dation of cardiolipin and the associated impairment of mito-
chondrial function, it thus seems likely that β-cells must have
some means of repairing or replacing oxidized cardiolipin
molecules in order to maintain mitochondrial function.
It has been proposed that the consecutive actions ofmito-
chondrial phospholipid glutathione peroxidase (PHGPx or
Gpx4) and a phospholipase A2 (PLA2) are required to elim-
inate oxidized fatty acids from mitochondrial phospholipids
under physiological conditions [83]. Gpx4 is a selenoprotein
in the glutathione peroxidase (Gpx) family that protects
biomembranes, particularly in mitochondria [84]. The PLA2
family comprises a diverse group of enzymes that catalyze
hydrolysis of the sn-2 fatty acyl bond of phospholipids to
generate a free fatty acid and a 2-lysophospholipid [85, 86].
Because the PUFAs in phospholipids tend to be located in the
sn-2 position, it is not surprising that members of the PLA2
family can hydrolyze oxidized sn-2 fatty acid substituents
[85, 87] and are thought to be involved in the repair of
oxidized membrane phospholipids [88–90].
Among PLA2 family members, Group VIA PLA2
(iPLA2β) is attracting increasing interest as a potentially criti-
cal participant in mitochondrial cardiolipin homeostasis [57,
62, 91, 92]. In eukaryotes, cardiolipin is synthesized de novo
from phosphatidylglycerol (PG) and cytidine diphosphate-
diacylglycerol (CDP-DAG) by cardiolipin synthase on the
inner face of the inner mitochondrial membrane [93].
Nascent cardiolipin does not contain PUFAs in its four
acyl chains, and the enrichment of PUFA in cardiolipin
is thought to be achieved by a remodeling process [94].
Currently, two potential mechanisms, Tafazzin- (TAZ-) and
iPLA2β/MLCLAT-mediated mechanisms, have been pro-
posed to participate in cardiolipin remodeling [93].
In the TAZ pathway, newly synthesized cardiolipin is
proposed to be deacylated and reacylated by TAZ. It appears
that this mechanism is essential for optimal mitochondrial
function in heart because Barth Syndrome, which is char-
acterized by a severe cardiomyopathy [95, 96], is caused by
a mutated TAZ gene that encodes a putative mitochondrial
phospholipid acyltransferase with both deacylation and
reacylation activities [95, 97]. In the iPLA2β/MLCLAT-
mediated pathway, newly synthesized cardiolipin is proposed
to be deacylated by iPLA2β to MLCL that is reacylated to
cardiolipin by aMLCL acyltransferase (MLCLAT) (Figure 2).
It has recently been recognized thatmutations in the PLA2G6
gene that encodes iPLA2β underlie the neurodegenerative
disease infantile neuroaxonal dystrophy (INAD) [98] and
that a similar disorder develops in mice with a disrupted
iPLA2β gene (Malik et al. [99]). It has been suggested that
iPLA2β also plays a role in cardiolipin remodeling both
in a Drosophila model of the Barth Syndrome [92] and
in the spontaneously hypertensive rat heart failure model
[91].
We have also reported observations that are consistent
with a role for iPLA2β in β-cell mitochondrial function
that include that iPLA2β resides in mitochondria in INS-
1 insulinoma cells and that its activity provides protec-
tion against the eﬀects of staurosporine to induce loss of
mitochondrial membrane potential, release of cytochrome
c and Smac/DIABLO into cytosol, peroxidation of mito-
chondrial membranes, and apoptosis [62]. Staurosporine is
an inhibitor of various isoforms of Protein Kinase C and
strongly stimulates mitochondrial generation of ROS [100].
Both Barth Syndrome and INAD are human genetic
disorders that are often fatal in childhood [95, 98] at an
age before type I DM might be manifest, which requires
loss of about 80–90% of the islet β-cell mass at the age of
onset [101]. Animal models that have been used to evaluate
the potential involvement of iPLA2β in disease processes
include administration of a suicide substrate bromoenol
lactone (BEL) inhibitor of iPLA2β [102] and iPLA2β-null
(iPLA2β −/−) mice generated by homologous recombination
to disrupt the iPLA2β gene [103]. These iPLA2β-null mice
develop a disorder similar to INAD [99, 104], exhibit several
other phenotypic abnormalities [103, 105–113], and have
permitted evaluation of the role of iPLA2β in β-cell failure
in vivo [57, 103, 114, 115].
We have observed that acute pharmacologic inhibition
of iPLA2β in mice impairs glucose tolerance by suppressing
insulin secretion and that insulin sensitivity is not aﬀected
under these conditions, which suggests that iPLA2β defi-
ciency adversely aﬀects glucose-induced insulin secretion by
β-cells [102]. Consistent with that interpretation, studies
with iPLA2β−/− mice that are genetically deficient in iPLA2β
expression because of homozygous disruption of the iPLA2β
gene by homologous recombination [103] have revealed that
they exhibit greater impairment in islet function, as reflected
by fasting blood glucose levels and glucose tolerance testing
responses, than do wild-type mice in response to metabolic
stress imposed by low-dose streptozotocin (STZ) treatment,
by consumption of a high-fat diet, or by staurosporine
administration [57, 114, 115].
Moreover, findings with pancreatic islets isolated from
iPLA2β−/− mice corroborate the involvement of iPLA2β in
glucose-stimulated insulin secretion because iPLA2β−/− islets
exhibit diminished secretory responses compared to wild-
type islets [57, 114, 115]. In addition, incubation with
elevated concentrations of glucose and free fatty acids in
vitro results in higher levels of β-cell apoptosis and of
peroxidation of mitochondrial membrane phospholipids
with islets isolated from iPLA2β−/− mice compared to those
fromwild-typemice [57]. These findings suggest that iPLA2β
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Figure 2: Schematic summary of the proposed role of mitochondrial cardiolipin oxidation in β-cell failure in type 2 diabetes mellitus.
Oxidative stress results in increased mitochondrial ROS generation in β-cells. With moderate oxidative stress, ROS oxidize polyunsaturated
fatty acid (PUFA) substituents in mitochondrial cardiolipin molecules, which may generate signals that mitigate ROS production via eﬀects
on respiratory electron transport chain complexes or on uncoupling protein 2 (UCP2) (dotted arrows). After delivery of the signal from the
ROS-PUFA interaction, the oxidized cardiolipin molecule is repaired in a pathway in which iPLA2β excises the oxidized PUFA residue to
yielded monolysocardiolipin (MLCL), which is then reacylated with an unoxidized PUFA substituent by MLCL acyltransferase (MLCLAT)
to complete the oxidation and repair cycle. Under conditions of overwhelming oxidative stress imposed by high metabolic loads, the rate
of cardiolipin oxidation exceeds the capacity of the repair mechanism and oxidized cardiolipin molecules accumulate and compromise
mitochondrial membrane integrity, and this leads to cytochrome c (Cyt. c) release into the cytosol and induction of apoptosis, which
eventuates in β-cell failure and the development of T2DM. Circumstances in which the capacity of the repair mechanism is overwhelmed in
this way would include reductions in iPLA2β activity caused by genetic deficiency, pharmacologic inhibition, or yet to be defined regulatory
influences on expression. Block arrows denote the iPLA2β-mediated deacylation; line arrows denote the stimulatory pathway. SFAs: saturated
fatty acids.
plays an important role in maintenance of β-cell mito-
chondrial membrane integrity and that iPLA2β deficiency
increases β-cell susceptibility to injury by ROS generated
by mitochondria in response to metabolic stress [57, 115].
This could lead to increased vulnerability to induction of
apoptosis under conditions of metabolic stress that lead to
β-cell failure and T2DM [57, 115]. β-cell mitochondrial
membrane peroxidation is also more readily induced under
conditions in which iPLA2β is inhibited pharmacologically
with the suicide substrate BEL [57].
It has been suggested that oxidation of PUFA in mito-
chondrial cardiolipin and other phospholipids may serve to
trap ROS in order to protect mitochondrial proteins or DNA
from oxidative injury or that reaction of PUFAwith ROSmay
generate signals to respiratory chain proteins and UCP2 that
mitigate ROS generation and increase proton leak [49, 77,
116–118]. A repair mechanism in which iPLA2β excised oxi-
dized fatty acid substituents from mitochondrial cardiolipin
and other phospholipids would generate monolysocardi-
olipin (MLCL) that could be reacylated with an unoxidized
PUFA substituent might complete a cycle that could modu-
late the levels and eﬀects of ROS during stress responses.
Under conditions in which the rates of ROS generation
and oxidation of PUFA in mitochondrial cardiolipin and
other phospholipids exceed the capacity of the repair system,
accumulation of oxidized phospholipids could eventually
impair the integrity of mitochondrial membranes and result
in release of cytochrome c into cytosol and induction of
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β-cell apoptosis. One circumstance in which the capacity
of this repair system would be reduced is when iPLA2β
activity is low because of pharmacologic inhibition, genetic
deficiency, or still to be defined regulatory influences. Under
such conditions, accumulation of oxidized mitochondrial
phospholipids and leakage of cytochrome c could result in
accelerated induction of apoptosis that ultimately leads to β-
cell failure and T2DM (Figure 2).
Of interest in this regard are findings with the db/db
mouse, which is a model of obesity, dyslipidemia, and
diabetes in which there is a defective leptin receptor. Islets
isolated from db/db mice express lower levels of iPLA2β
than do islets from control mice [57], and this could impair
cardiolipin remodeling and repair in db/db β-cells and
increase their susceptibility to oxidative injury, which could
accelerate obesity-associated β-cell loss and the development
of T2DM.
6. Conclusions and Therapeutic Implications
Modification of mitochondrial cardiolipin molecular species
by oxidation and other processes is now recognized to be
associated with many human diseases, including diabetes
mellitus [55, 58, 60]. Cardiolipin is a critical structural com-
ponent of mitochondrial membranes and plays important
roles in regulating ATP synthesis and the mitochondrial
pathway of apoptosis [49, 119]. Metabolic stresses imposed
by obesity and hyperglycemia are often accompanied by
increased rates of mitochondrial ROS production [69].
PUFAs are especially susceptible to oxidation by ROS because
they contain a highly reactive bisallylic methylene moiety
from which hydrogen is readily abstracted to yield a center
for initiation of peroxidation chain reactions, and cardiolipin
is enriched in PUFA substituents.
A repair mechanism in which iPLA2β excises oxidized
PUFA substituents of cardiolipin to yield an MLCL interme-
diate that can be reacylated with an unoxidized PUFA sub-
stituent may be critical for the maintenance of mitochondrial
membrane integrity, and it seems likely that some such repair
mechanisms would be necessitated by the close spatial prox-
imity of mitochondrial cardiolipin to the locus of ROS gen-
eration. Failure of this repair mechanism could compromise
mitochondrial membrane integrity and facilitate release of
cytochrome c into cytosol and induction of apoptosis. Obser-
vations from several laboratories [57, 62, 91, 92, 102, 114,
115] suggest that iPLA2β-catalyzed deacylation participates
in a cardiolipin remodeling and repair cycle that maintains
an optimal mitochondrial functional status in β-cells.
Reduced iPLA2β activity resulting from genetic defi-
ciency, as in INAD patients or iPLA2β −/− mice, or downreg-
ulated expression, as in db/db mouse islets, could impair this
cardiolipin repair mechanism and result in accumulation of
oxidized cardiolipin species that compromise mitochondrial
membrane integrity. The ensuing release of cytochrome c
into cytosol and induction of apoptosis might result in the
neurodegeneration in INAD and in β-cell loss during the
development of T2DM. Further study of cardiolipin remod-
eling and repair and the role of iPLA2β in these processes
could increase our understanding of the pathogenesis of
diabetes mellitus and neurodegeneration and suggest novel
strategies for design of therapeutic interventions to prevent
or retard the development of T2DM and neurodegenerative
diseases in humans.
An example of such a potential intervention would be
administration of an agent that accumulated in mitochon-
dria and protected them from injurious eﬀects of ROS.
The antioxidant NtBHA accumulates in mitochondria, and
we have found that it attenuates staurosporine-induced
apoptosis and prevents peroxidation of mitochondrial phos-
pholipids in islets from iPLA2β−/− mice [57]. A similar
approach to protecting mitochondrial cardiolipin and other
phospholipids from oxidation might represent an attractive
therapeutic strategy in humans with metabolic or neurode-
generative diseases. Such approaches might be complicated
by the fact that some eﬀects of ROS are not injurious but
represent essential signaling roles in physiological regulatory
mechanisms. For example, mitochondrial ROS generation
has been suggested to be an essential signal in the glucose-
stimulated insulin secretory pathway in β-cells and also to be
involved in insulin signaling and sensitivity [120].
Thus, manipulating ROS production or interaction with
intracellular targets in vivo could have unexpected and
unwanted adverse eﬀects, and the ability to target such
interventions with high selectivity to specific intracellular
processes, such as inhibition of mitochondrial phospholipid
oxidation, might be desirable. It is of interest in this regard
that specific delivery of antioxidants to mitochondria, such
as mitoquinone (Mito-Q) and mitovitamin E (mitoVit-E),
has been demonstrated to reduce oxidative stress and to
improve cardiac function [121, 122] and might be similarly
beneficial in β-cells. In addition, melatonin specifically
inhibits mitochondrial cardiolipin oxidation and has also
been found to prevent induction of the mitochondrial
permeability transition (MPT) and release of cytochrome
into cytosol and to protect against myocardial ischemia-
reperfusion injury [120, 123].
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